Stage III dMMR Colon Cancer (Adjuvant)
RHHBYRoche HoldingCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Tecentriq/Atezolizumab (PD-L1 Antibody) in Stage III dMMR Colon Cancer (Adjuvant). The expected timing is based on the latest available company guidance and may change.
05/18/26:- ATOMIC Phase 3 HRQOL poster at ASCO May 30, 2026. 06/11/26:- FDA accepted sBLA for adjuvant Tecentriq+FOLFOX6 in stage III dMMR colon cancer; decision October 9, 2026. 07/23/26:- ATOMIC Phase 3 priority review was reiterated; FDA decision will occur October 9, 2026.
Verification
Confirm timing and program details against the company announcement or filing.